Optimal glycaemic and blood pressure but not lipid targets are related to a lower prevalence of diabetic microvascular complications

Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102241. doi: 10.1016/j.dsx.2021.102241. Epub 2021 Aug 8.

Abstract

Background: Diabetic microvascular complications are a major cause of morbidity and are related to glycaemic control and cardiovascular risk factors.

Aims: We sought to determine the association of microvascular complications in relation to control of glycemia, blood pressure and lipids in T2DM patients attending secondary care in Qatar.

Methods: This is a cross-sectional study undertaken in patients with T2DM attending Qatar's National Diabetes Centres. Patients underwent assessment of glycemia, blood pressure and lipids and prevalence of diabetic peripheral neuropathy (DPN), retinopathy and microalbuminuria.

Results: We included 1114 subjects aged 52.1 ± 11.3 years with a duration of diabetes 10.0 ± 7.6 years and had a prevalence of 25.8% for DPN, 34.3% for painful DPN, 36.8% for microalbuminuria and 25.1% for retinopathy. Patients who achieved an HbA1c ≤ 7.0% compared to >7% had a significantly lower prevalence of DPN (P < 0.01), painful DPN (P < 0.01), retinopathy (P < 0.01) and microalbuminuria (P < 0.007). Patients who achieved a systolic BP ≤ 140 mmHg compared to >140 mmHg had a significantly lower prevalence of DPN (P < 0.001), painful DPN (P < 0.001), retinopathy (P < 0.001) and microalbuminuria (P < 0.001). Patients who achieved an LDL ≤2.6 mmol/l compared to >2.6 mmol/l had a significantly higher prevalence of DPN (P < 0.03), but no difference in other outcomes. There was no difference in microvascular complications between those who achieved a HDL-C ≥ 1.02 mmol/l, and among those who achieved triglycerides ≤1.7 mmol/l.

Conclusions: Optimal control of glycemia and blood pressure, but not lipids is associated with a lower prevalence of diabetic microvascular complications.

Keywords: Blood pressure; Diabetic neuropathy; Glycemia; Lipids; Microalbuminuria; Retinopathy; Type 2 diabetes.

MeSH terms

  • Biomarkers / blood
  • Blood Glucose / analysis
  • Blood Pressure*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Diabetic Angiopathies / epidemiology
  • Diabetic Angiopathies / pathology
  • Diabetic Angiopathies / prevention & control*
  • Diabetic Neuropathies / epidemiology
  • Diabetic Neuropathies / pathology
  • Diabetic Neuropathies / prevention & control*
  • Diabetic Retinopathy / epidemiology
  • Diabetic Retinopathy / pathology
  • Diabetic Retinopathy / prevention & control*
  • Female
  • Follow-Up Studies
  • Glycated Hemoglobin / analysis
  • Glycemic Control / standards*
  • Humans
  • Lipids / analysis*
  • Male
  • Middle Aged
  • Prevalence
  • Prognosis
  • Qatar / epidemiology
  • Triglycerides / metabolism

Substances

  • Biomarkers
  • Blood Glucose
  • Glycated Hemoglobin A
  • Lipids
  • Triglycerides
  • hemoglobin A1c protein, human